Lutetium-177 vipivotide tetraxetan, trade name Pluvicto, also known as 177Lu-PSMA-617, is a theranostic (i.e. both therapeutic and diagnostic) agent approved as a treatment for adult patients with treatment-resistant advanced metastatic prostate cancer. The treatment works by binding to cancer ...